Review on management of GERD
Maharishi Arvind Institute of Pharmacy, Jaipur, Rajasthan India.
Review
World Journal of Biology Pharmacy and Health Sciences, 2022, 12(03), 216-223.
Article DOI: 10.30574/wjbphs.2022.12.3.0232
Publication history:
Received on 26 October 2022; revised on 12 December 2022; accepted on 14 December 2022
Abstract:
Gastroesophageal reflux disease (GERD) is a chronic disorder of the upper gastrointestinal tract with global distribution. The incidence is on the increase in different parts of the world. It is characterized by heartburn and/or regurgitation symptoms is one of the most common gastrointestinal disorders managed by gastroenterologists and primary care physicians. Optimization of therapy (improving compliance and timing of PPI doses), or increasing PPI dosage to twice daily in select circumstances, can reduce persistent symptoms. In patients with residual reflux, medications like H2 blockers, Prokinetics and baclofen may be used. In those with functional heartburn or reflux sensitivity neuro-modulators form an integral part of any therapeutic approach.
Keywords:
Gastroesophageal reflux; Proton pump inhibitors; Prokinetics; Esophageal; Management
Full text article in PDF:
Copyright information:
Copyright © 2022 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0